|
- Investigating nerve fibre damage in chemotherapy-induced peripheral . . .
This study aims to: 1) assess peripheral nerve fibre damage in patients receiving neurotoxic chemotherapy focusing on Aδ and C fibres due to their involvement in pain perception and 2) explore potential differences between cancer chemotherapy type
- Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving . . .
This prospective study from a single center in Kosovo aimed to evaluate CIPN in 120 patients receiving 4-6 cycles of platinum-based and taxane-based chemotherapy MATERIAL AND METHODS One hundred twenty patients underwent neurological examination and nerve conduction studies (NCS) before chemotherapy, and after 4 to 6 cycles of treatment
- Chemotherapy-induced peripheral neuropathy: A prospective study using . . .
Background: Chemotherapy induced peripheral neuropathy (CIPN) is the commonest neurological complication of cancer treatment Its accurate diagnosis remains a clinical challenge Conventional methods like nerve conduction studies and quantitative sensory testing are limited in their ability to detect subclinical changes and have not been shown to correlate with severity of patients’ symptoms
- Updates in the treatment of chemotherapy-induced peripheral neuropathy . . .
Chemotherapy-induced peripheral neuropathy (CIPN) is a common toxicity associated with treatment with platinum-based agents, taxanes, vinca alkaloids, and other specific agents The long-term consequences of this condition can result in decreased
- Chemotherapy-Induced Peripheral Neuropathy: Current Evidence-Based . . .
Description Chemotherapy-Induced Peripheral Neuropathy (CIPN) is one of the most common and debilitating side effects associated with neurotoxic chemotherapy in cancer patients and survivors CIPN results from axonal damage and neuronal degradation caused by cytotoxic chemotherapy, significantly diminishing the quality of life for many patients
- Quantification of Small Fiber Neuropathy in Chemotherapy-Treated . . .
Chemotherapy-induced peripheral neuropathy (CIPN) is a major, dose-limiting side effect of treatment with neurotoxic cancer treatments, including platinum compounds, taxanes, vinca alkaloids, thalidomide, and bortezomib 79 Symptoms of CIPN include paresthesia, numbness and weakness in the extremities, typically resulting from damage to large sensory as well as motor nerve fibers However
- Chemotherapy-Induced Peripheral Neuropathy: Mechanisms and Therapeutic . . .
Chemotherapy-induced peripheral neuropathy (CIPN) is a serious and often persistent adverse consequence of certain chemotherapeutic agents It is a major dose-limiting factor of many first-line chemotherapies, affecting 20–50% of patients at standard doses and nearly all patients at high doses
- Investigating nerve fibre damage in chemotherapy-induced peripheral . . .
Request PDF | On May 20, 2018, Sabrina Ramnarine and others published Investigating nerve fibre damage in chemotherapy-induced peripheral neuropathy (CIPN): A prospective study | Find, read and
|
|
|